Fight against cancer an enduring investment motivation in September quarter despite markets
Cancer remains one of the most pressing public health challenges worldwide, affecting millions of lives...
Cancer remains one of the most pressing public health challenges worldwide, affecting millions of lives...
Prescient Therapeutics is a Melbourne-based drug developer focused on cancer, with several platforms and products...
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has had its abstract for PTX-100 published on the American Society...
Prescient Therapeutics (ASX: PTX) reported encouraging results in several key targeted and cell therapies in...
It’s a wrap for the September quarter. Here are some of the latest highlights from...
Prescient Therapeutics (ASX: PTX) has been invited to present clinical data at the prestigious American...
Clinical stage oncology company Prescient Therapeutics will showcase the results of its Phase 1b study in...
Australian clinical stage oncology company Prescient Therapeutics (ASX: PTX) is set to present the exciting results from...
Prescient Therapeutics (ASX: PTX) to present Phase 1b cancer trial data at prestigious haematology conference
Prescient Therapeutics (ASX:PTX) has announced that its abstract for the results of a Phase 1b...
This investor centre was built by Reach Markets
©2022 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.